ARA‑290 (also known as Cibinetide or PH‑BSP) is a synthetic peptide derived from erythropoietin. It activates the body’s innate repair receptor to help reduce inflammation, support nerve function, improve metabolic health, and speed tissue repair—without increasing red blood cell production.

Why Researchers Choose ARA‑290

• Reduces inflammation & eases chronic pain – Acts on TRPV1 to dampen nerve pain and inflammatory signaling

• Improves neuropathy & nerve health – Phase 2 trials show increased corneal nerve density and reduced pain in diabetic neuropathy 

• Metabolic benefits – Lowers HbA1c and improves cholesterol profiles in type 2

• Promotes tissue repair – Enhances wound healing, angiogenesis, and organ protection in preclinical models

How It Works (Simple): Modeled after a small part of erythropoietin, ARA‑290 targets a specialized tissue repair receptor (TPR) to switch off inflammation and turn on healing pathways—without affecting red blood cells.

FAQs Q: How quickly do effects appear? A: Improvements in nerve pain, inflammation, and tissue repair have been seen in lab and clinical settings within 2–4 weeks 

Q: Is it safe? A: Tolerated well in both animal and human trials, with minimal side effects even at high doses

Order ARA‑290 16 mg today—support your research on inflammation, neuropathy, metabolic health, and tissue repair with confidence.